Melanoma News – Melanoma Research Victoria https://melanomaresearchvic.com.au Wed, 20 Jan 2021 06:47:36 +0000 en-US hourly 1 https://melanomaresearchvic.com.au/wp-content/uploads/2017/12/cropped-favicon-32x32.png Melanoma News – Melanoma Research Victoria https://melanomaresearchvic.com.au 32 32 Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) https://melanomaresearchvic.com.au/nivolumab-plus-ipilimumab-for-treatment-naive-metastatic-uveal-melanoma-an-open-label-multicenter-phase-ii-trial-by-the-spanish-multidisciplinary-melanoma-group-gem-1402 Thu, 21 Jan 2021 06:41:29 +0000 https://melanomaresearchvic.com.au/?p=16249 In this single-arm, phase II trial, researchers sought to evaluate the effectiveness of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.

The post Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) appeared first on Melanoma Research Victoria.

]]>
Source: MDLinx, January 2021

In this single-arm, phase II trial, researchers sought to evaluate the effectiveness of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.

In total, 52 patients with a median age of 59 years (range, 26-84 years) were registered.

During four inductions, nivo (1 mg/kg once every 3 weeks) and ipi (3 mg/kg once every 3 weeks) were given, followed by nivo (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.

READ THE ORIGINAL FULL ARTICLE

The post Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) appeared first on Melanoma Research Victoria.

]]>
New humanized mouse model provides insight into immunotherapy resistance https://melanomaresearchvic.com.au/new-humanized-mouse-model-provides-insight-into-immunotherapy-resistance Thu, 21 Jan 2021 06:37:07 +0000 https://melanomaresearchvic.com.au/?p=16247 Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma.

The post New humanized mouse model provides insight into immunotherapy resistance appeared first on Melanoma Research Victoria.

]]>
Source: EurekAlert!, January 2021

Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma.

It has revealed a central role for mast cells.

These findings were published today in the journal Nature Communications.

READ THE ORIGINAL FULL ARTICLE

The post New humanized mouse model provides insight into immunotherapy resistance appeared first on Melanoma Research Victoria.

]]>
Regression may predict good prognosis in stage 1 and 2 cutaneous melanomas https://melanomaresearchvic.com.au/regression-may-predict-good-prognosis-in-stage-1-and-2-cutaneous-melanomas Thu, 21 Jan 2021 06:31:34 +0000 https://melanomaresearchvic.com.au/?p=16245 Disease regression was associated with improved recurrence-free survival and overall survival among certain patients with stage 1 and 2 cutaneous melanomas, according to a study.

The post Regression may predict good prognosis in stage 1 and 2 cutaneous melanomas appeared first on Melanoma Research Victoria.

]]>
Source: Healio, January 2021

Disease regression was associated with improved recurrence-free survival and overall survival among certain patients with stage 1 and 2 cutaneous melanomas, according to a study.

“Although regression is commonly observed in cutaneous melanoma, it is uncertain whether it is associated with patient prognosis,” Mary-Ann El Sharouni, MD, of the Melanoma Institute Australia at The University of Sydney and the department of dermatology at University Medical Center Utrecht at Utrecht University, the Netherlands, and colleagues wrote.

In the cohort study involving 17,271 Dutch patients and 4,980 Australian patients with stage 1 and 2 primary cutaneous melanomas, the researchers aimed to determine whether histologically confirmed regression was associated with better or worse survival.

READ THE ORIGINAL FULL ARTICLE

The post Regression may predict good prognosis in stage 1 and 2 cutaneous melanomas appeared first on Melanoma Research Victoria.

]]>
Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival https://melanomaresearchvic.com.au/incidence-of-thromboembolism-in-patients-with-melanoma-on-immune-checkpoint-inhibitor-therapy-and-its-adverse-association-with-survival Wed, 20 Jan 2021 06:29:17 +0000 https://melanomaresearchvic.com.au/?p=16243 Thromboembolism (TE) in cancer significantly contributes to morbidity and mortality. Little is known about the incidence of arterial TE (ATE) and venous TE (VTE) in patients with melanoma on immune checkpoint inhibitor (ICI) therapy.

The post Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival appeared first on Melanoma Research Victoria.

]]>
Source: docwirenews, January 2021

Thromboembolism (TE) in cancer significantly contributes to morbidity and mortality. Little is known about the incidence of arterial TE (ATE) and venous TE (VTE) in patients with melanoma on immune checkpoint inhibitor (ICI) therapy.

We conducted a retrospective cohort study of patients with melanoma receiving ICI from July 2015 through December 2017 at the Cleveland Clinic.

TE, including VTE events of deep venous thrombosis, pulmonary embolism, visceral vein thrombosis, and ATE events of myocardial infarction, stroke, peripheral arterial embolism, or transient ischemic attack after ICI initiation were identified.

READ THE ORIGINAL FULL ARTICLE

The post Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival appeared first on Melanoma Research Victoria.

]]>
Philogen Announces the Completion of a Second Interim Analysis of Its Phase III Clinical Program With Nidlegy for the Treatment of Melanoma https://melanomaresearchvic.com.au/philogen-announces-the-completion-of-a-second-interim-analysis-of-its-phase-iii-clinical-program-with-nidlegy-for-the-treatment-of-melanoma Wed, 20 Jan 2021 06:22:47 +0000 https://melanomaresearchvic.com.au/?p=16241 Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-based therapeutics, is pleased to announce that 50% of the expected events for the primary outcome analysis of the PIVOTAL study were reached in December 2020.

The post Philogen Announces the Completion of a Second Interim Analysis of Its Phase III Clinical Program With Nidlegy for the Treatment of Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: PR Newswire, January 2021

hilogen S.p.A., a clinical-stage biotechnology company focused on antibody-based therapeutics, is pleased to announce that 50% of the expected events for the primary outcome analysis of the PIVOTAL study were reached in December 2020.

In this phase III clinical trial, the effect of Nidlegy™ is evaluated in melanoma patients with locally advanced, fully resectable metastatic cancer, and at the time of the second interim analysis, had already recruited 149 out of the anticipated 214 patients (one additional patient was enrolled recently).

As a consequence, the second interim data analysis foreseen by the clinical protocol was carried out and submitted to the Data and Safety Monitoring Board of the study for their consideration.

READ THE ORIGINAL FULL ARTICLE

The post Philogen Announces the Completion of a Second Interim Analysis of Its Phase III Clinical Program With Nidlegy for the Treatment of Melanoma appeared first on Melanoma Research Victoria.

]]>
World first melanoma success in Australia prompts new trial https://melanomaresearchvic.com.au/world-first-melanoma-success-in-australia-prompts-new-trial Wed, 20 Jan 2021 06:04:55 +0000 https://melanomaresearchvic.com.au/?p=16239 A Sydney man who was seriously ill with advanced melanoma has made a remarkable recovery after receiving a drug reserved for breast and ovarian cancer.

The post World first melanoma success in Australia prompts new trial appeared first on Melanoma Research Victoria.

]]>
Source: 9NEWS, January 2021

A Sydney man who was seriously ill with advanced melanoma has made a remarkable recovery after receiving a drug reserved for breast and ovarian cancer.
Charles Hanna had exhausted all treatments for his cancer, but tumours in his upper abdomen have now vanished.
His world-first case has prompted the Melanoma Institute to run a new clinical trial.

READ THE ORIGINAL FULL ARTICLE

 

The post World first melanoma success in Australia prompts new trial appeared first on Melanoma Research Victoria.

]]>
Sydney man recovers from advanced melanoma in unconventional treatment https://melanomaresearchvic.com.au/sydney-man-recovers-from-advanced-melanoma-in-unconventional-treatment Tue, 19 Jan 2021 05:28:50 +0000 https://melanomaresearchvic.com.au/?p=16233 A Sydney man has recovered from advanced melanoma thanks to a drug usually used for breast and ovarian cancer, prompting the Melanoma Institute to run a new clinical trial.

The post Sydney man recovers from advanced melanoma in unconventional treatment appeared first on Melanoma Research Victoria.

]]>
Source: 9NEWS, January 2021

A Sydney man has recovered from advanced melanoma thanks to a drug usually used for breast and ovarian cancer, prompting the Melanoma Institute to run a new clinical trial.

SEE THE ORIGINAL FULL UPDATE

 

The post Sydney man recovers from advanced melanoma in unconventional treatment appeared first on Melanoma Research Victoria.

]]>
Does Screening for Skin Cancer Result in Melanoma Overdiagnosis? https://melanomaresearchvic.com.au/does-screening-for-skin-cancer-result-in-melanoma-overdiagnosis Tue, 19 Jan 2021 05:04:23 +0000 https://melanomaresearchvic.com.au/?p=16231 When the COVID-19 pandemic first hit, cancer screening in the US came to an abrupt halt.

The post Does Screening for Skin Cancer Result in Melanoma Overdiagnosis? appeared first on Melanoma Research Victoria.

]]>
Source: Medscape, January 2021

When the COVID-19 pandemic first hit, cancer screening in the US came to an abrupt halt.

That experience, coupled with the financial fallout of the pandemic, has led some doctors to reassess business as usual.

In particular, a trio has taken aim at skin cancer screening — arguing that it should stop — in a ‘sounding board’ commentary published online January 7 in the New England Journal of Medicine.

READ THE ORIGINAL FULL ARTICLE

 

The post Does Screening for Skin Cancer Result in Melanoma Overdiagnosis? appeared first on Melanoma Research Victoria.

]]>
Study reveals significant role of ADAMTS1 protein in uveal melanoma https://melanomaresearchvic.com.au/study-reveals-significant-role-of-adamts1-protein-in-uveal-melanoma Tue, 19 Jan 2021 04:58:37 +0000 https://melanomaresearchvic.com.au/?p=16229 Scientists from the University of Granada and GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), in a study led by Juan Carlos Rodríguez-Manzaneque, have demonstrated the significant role of a protein called ADAMTS1 in uveal melanoma, one of the rarest and most aggressive cancers that exist, which develops in the eye.

The post Study reveals significant role of ADAMTS1 protein in uveal melanoma appeared first on Melanoma Research Victoria.

]]>
Source: News Medical Life Sciences, January 2021

Scientists from the University of Granada and GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), in a study led by Juan Carlos Rodríguez-Manzaneque, have demonstrated the significant role of a protein called ADAMTS1 in uveal melanoma, one of the rarest and most aggressive cancers that exist, which develops in the eye.

tumors are composed not only of a mass of cells that grow uncontrollably but also of the environment they create during their growth—together creating what is known as the ‘tumor microenvironment’.

Within this environment, there are proteins that remodel it, known as extracellular proteases, which are capable of inhibiting or contributing to tumor growth and metastasis.

READ THE ORIGINAL FULL ARTICLE

The post Study reveals significant role of ADAMTS1 protein in uveal melanoma appeared first on Melanoma Research Victoria.

]]>
The Yin and Yang of BRAF, MEK and CDK4-6 targeted therapy https://melanomaresearchvic.com.au/the-yin-and-yang-of-braf-mek-and-cdk4-6-targeted-therapy Mon, 18 Jan 2021 04:49:44 +0000 https://melanomaresearchvic.com.au/?p=16222 A new paper from the McArthur & Sheppard Laboratory, by Emily Lelliott et. al.

The post The Yin and Yang of BRAF, MEK and CDK4-6 targeted therapy appeared first on Melanoma Research Victoria.

]]>
A new paper from the McArthur & Sheppard Laboratory, by Emily Lelliott et. al.

Download PDF File

The post The Yin and Yang of BRAF, MEK and CDK4-6 targeted therapy appeared first on Melanoma Research Victoria.

]]>